公开(公告)号：US06441038B1

公开(公告)日：2002-08-27

申请号：US09686629

申请日：2000-10-12

Applicant: Cari Loder ,  David F. Horrobin

Inventor： Cari Loder ,  David F. Horrobin

IPC: A61K31195

CPC classification number: A61K31/55 ,  A61K45/06 ,  A61K2300/00

Abstract: A method of treatment of disorders of neurological origin and drug formulations for use in the method are disclosed. These conditions comprise fatigue and associated syndromes of pain, weakness and depressed mood which are associated with chronic fatigue syndrome, brain injury and stroke, stress, fibromyalgia, and irritable bowel syndrome. The treatment comprises administering to a patient in need thereof a selective inhibitor of noradrenaline reuptake combined with either phenylalanine or tyrosine in the same dosage form or the same pack.# The noradrenergic drug may be selected from lofepramine, desipramine or reboxetine. The selective inhibitor may be a combined inhibitor of both noradrenaline and serotonin reuptake such as venlafaxine, duloxetine or milnacipran, or an inhibitor of both noradrenaline and dopamine reuptake such as bupropion.

Abstract translation: 公开了一种治疗神经源性疾病的方法和用于该方法的药物制剂。 这些病症包括与慢性疲劳综合征，脑损伤和中风，压力，纤维肌痛和肠易激综合征相关的疲劳和相关的疼痛，虚弱和抑郁情绪综合征。 该治疗包括向有需要的患者施用去甲肾上腺素再摄取的选择性抑制剂与相同剂型或相同包装中的苯丙氨酸或酪氨酸组合。＃去甲肾上腺素能药可以选自洛哌匹灵，地昔帕明或瑞波西汀。 选择性抑制剂可以是去甲肾上腺素和5-羟色胺再摄取的组合抑制剂，如文拉法辛，度洛西汀或米那普仑，或去甲肾上腺素和多巴胺再摄入如安非他酮的抑制剂。

公开(公告)号：US06630157B1

公开(公告)日：2003-10-07

申请号：US09463300

申请日：2000-08-15

Applicant: David F. Horrobin ,  Hans-Jurgen Tritschler

Inventor： David F. Horrobin ,  Hans-Jurgen Tritschler

IPC: A61K4700

CPC classification number: A61K31/202 ,  A61K31/385 ,  Y10S514/866 ,  A61K31/20 ,  A61K2300/00

Abstract: Compostions of GLA and/or other EFAs with TA or related compounds, and their use in therapy or nutrition or in preparation of composition for therapy or nutrition, especially to improve cell membrane EFA concentration and/or (particularly in diabetic complications) impaired nerve function and blood flow.

Abstract translation: GLA和/或其他具有TA或相关化合物的EFAs的组合及其在治疗或营养中的用途或用于治疗或营养的组合物的用途，特别是改善细胞膜EFA浓度和/或（特别是在糖尿病并发症中）损害神经功能 和血流。

公开(公告)号：US06407075B1

公开(公告)日：2002-06-18

申请号：US09254286

申请日：1999-07-06

Applicant: Catherine A. Scott ,  David F. Horrobin

Inventor： Catherine A. Scott ,  David F. Horrobin

IPC: A61K3170

CPC classification number: A61K31/201 ,  A61K31/202

Abstract: The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.

Abstract translation: 制备用于治疗和预防分子中具有14至26个碳链长度并具有2-6个双键的多不饱和脂肪酸的抗癌化疗副反应的药物用于顺式或反式构型，以及 这种治疗或预​​防的方法，其中所述脂肪酸用作活性物质。

公开(公告)号：US5670540A

公开(公告)日：1997-09-23

申请号：US440987

申请日：1995-05-15

Applicant: David F. Horrobin ,  Philip Knowles ,  Mehar Singh Manku ,  Austin McMordie

Inventor： David F. Horrobin ,  Philip Knowles ,  Mehar Singh Manku ,  Austin McMordie

IPC: A23D9/00 ,  A23L1/30 ,  A61K8/11 ,  A61K8/30 ,  A61K8/37 ,  A61K31/23 ,  A61K31/232 ,  A61P17/00 ,  A61P25/28 ,  A61P29/00 ,  A61P37/08 ,  C07C69/52 ,  C07C69/587 ,  C11C3/00 ,  A61K31/22

CPC classification number: A61K31/232 ,  A23L33/12 ,  A61K31/23 ,  C07C69/52 ,  C07C69/587

Abstract: A triglyceride for use in therapy or as a nutritional supplement, or a composition containing a triglyceride, wherein the triglyceride comprises a fatty acid selected from gamma-linolenic acid and the n-6 EPAs naturally derived therefrom and stearidonic acid and the n-3 EFAs naturally derived therefrom, forming a triple ester with glycerol or alternatively forming a double ester in which the other esterifying acide is a single residue of linoleic acid, with the proviso that the di-gammalinolenoyl-mono-linoleoyl glyceride if selected is used as a preparation containing more than 20% by weight thereof.

Abstract translation: 用于治疗或作为营养补充剂的甘油三酸酯或含有甘油三酯的组合物，其中所述甘油三酯包含选自γ-亚麻酸和从其天然衍生的n-6EPAs的脂肪酸和十八碳四烯酸和n-3EFA 由甘油形成三酯，或者形成双酯，其中另一种酯化酰亚胺是亚油酸的单一残基，条件是如果选择的话，可以使用二元聚乙烯酰基单亚油酰甘油酯作为制剂 含有20重量％以上。

公开(公告)号：US5618558A

公开(公告)日：1997-04-08

申请号：US106989

申请日：1993-08-16

Applicant: David F. Horrobin ,  Brenda E. Reynolds

Inventor： David F. Horrobin ,  Brenda E. Reynolds

IPC: A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61K31/23 ,  A61P3/00 ,  A61P3/14 ,  A61P19/10 ,  A61P43/00 ,  A61K9/20 ,  A61K9/48

CPC classification number: A61K31/20

Abstract: Increasing gut calcium absorption in humans or animals by the administration of GLA, DGLA or LA as such or in salt or other pharmacologically acceptabe form, optionally in association with EPA, DHA or other EFA in similar forms, specifically useful in treatment of osteoporosis.

Abstract translation: 通过施用GLA，DGLA或LA本身或以盐或其他药理学接受形式增加人或动物中的肠钙吸收，任选地与EPA，DHA或其他类似形式的EFA相关联，特别可用于治疗骨质疏松症。

公开(公告)号：US5594031A

公开(公告)日：1997-01-14

申请号：US422614

申请日：1995-04-13

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A01N37/52 ,  A01N43/40 ,  A61K20060101 ,  A61K8/19 ,  A61K8/362 ,  A61K31/185 ,  A61K33/00 ,  A61K33/14 ,  A61Q5/00 ,  A61Q5/02 ,  A61Q19/00 ,  C01D20060101 ,  C07D213/64 ,  C07D213/69 ,  C07D213/84 ,  C07D213/85 ,  C07F9/22 ,  C07F9/36 ,  C07F9/44

CPC classification number: A61K8/362 ,  A61K8/0229 ,  A61K8/19 ,  A61Q19/00 ,  A61Q19/001 ,  A61Q19/008 ,  A61Q5/006 ,  A61Q5/02 ,  Y10S514/864

Abstract: The invention relates to a method of skin treatment comprising the step of topically applying to skin affected by seborrheic dermatitis an amount of a composition comprising an excipient and from about 1% to 30% lithium ion, said amount being sufficient to reduce sebum production by said skin. The invention also relates to a method of skin treatment, which comprises the step of topically applying to skin affected by seborrheic dermatitis an amount of a composition comprising a topically acceptable excipient and an effective amount of a lithium salt.

Abstract translation: 本发明涉及一种皮肤治疗方法，其包括局部施用于受脂溢性皮炎影响的皮肤的步骤，该组合物含有一种赋形剂和约1％至30％的锂离子，所述量足以减少所述 皮肤。 本发明还涉及一种皮肤治疗方法，其包括局部施用于受脂溢性皮炎影响的皮肤的步骤，所述组合物含有局部可接受的赋形剂和有效量的锂盐。

公开(公告)号：US5580556A

公开(公告)日：1996-12-03

申请号：US367819

申请日：1995-01-03

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K38/21

CPC classification number: A61K31/20 ,  A61K38/21

Abstract: The use of one or more of gamma-linolenic acid, dihomo-gamma-linolenic acid and arachidonic acid for the manufacture of a medicament for use in enhancement of the anti-viral, anti-cancer or anti-inflammatory effects of interferons; the medicament containing or being for use with a medicament containing one or more interferons when not solely for enhancement of the effect of endogenous interferons.

Abstract translation: 使用一种或多种γ-亚麻酸，二氢-γ-亚麻酸和花生四烯酸来制造用于增强干扰素抗病毒，抗癌或抗炎作用的药物; 所述药物含有或用于含有一种或多种干扰素的药物，而不仅仅是为了增强内源性干扰素的作用。

公开(公告)号：US5516801A

公开(公告)日：1996-05-14

申请号：US365171

申请日：1994-12-28

Applicant: David F. Horrobin ,  Brenda E. Reynolds

Inventor： David F. Horrobin ,  Brenda E. Reynolds

IPC: A61K31/20

CPC classification number: A61K31/20

Abstract: Prevention and/or treatment of abnormal calcification in any tissue by the administration of (i) GLA and/or its EFA metabolites, and in particular the rapidly produced DGLA and/or (ii) EPA and/or its precursors, stearidonic acid and 20:4 n-3, and metabolites, docosahexaenoic acid (DHA) or docosapenmenoic acid (22:5 n-3), as such or in salt or other pharmacologically acceptable form. This is especially suitable for prevention or treatment of nephrocalcinosis and/or renal stones.

Abstract translation: 通过施用（i）GLA和/或其EFA代谢物，特别是快速产生的DGLA和/或（ii）EPA和/或其前体，十八碳四烯酸和20 ：4 n-3，以及代谢物，二十二碳六烯酸（DHA）或二十二碳二烯酸（22：5 n-3），或盐或其他药理学上可接受的形式。 这特别适用于预防或治疗肾钙质沉着症和/或肾结石。

公开(公告)号：US5466841A

公开(公告)日：1995-11-14

申请号：US187042

申请日：1994-01-27

Applicant: David F. Horrobin ,  Austin McMordie ,  Mehar S. Manku

Inventor： David F. Horrobin ,  Austin McMordie ,  Mehar S. Manku

IPC: A23J7/00 ,  A61K8/00 ,  A61K8/55 ,  A61K8/58 ,  A61K8/96 ,  A61K38/00 ,  A61Q19/00 ,  C07F9/10 ,  C07F9/113 ,  C07F9/117 ,  C07F9/02

CPC classification number: A61K8/553 ,  A23J7/00 ,  A61Q19/00 ,  C07F9/10 ,  C07F9/117

Abstract: A phospholipid comprising two different unsaturated fatty acids, the fatty acids being selected from the twelve n-6 and n-3 essential fatty acids, oleic acid, parinaric acid and combinic acid.

Abstract translation: 包含两种不同不饱和脂肪酸的磷脂，所述脂肪酸选自十二个n-6和n-3必需脂肪酸，油酸，对苯二酸和组合酸。

公开(公告)号：US5380757A

公开(公告)日：1995-01-10

申请号：US61110

申请日：1993-05-14

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K9/02 ,  A61K9/06 ,  A61K9/107 ,  A61K31/20 ,  A61K31/202 ,  A61P13/02 ,  A61P15/00

CPC classification number: A61K31/20

Abstract: Gamma-linolenic (GLA) and/or dihomo-gamma-linolenic acid (DGLA) may be used in the treatment of vulvar dystrophy and/or vaginal dryness. Other essential fatty acids of the n-6 or n-3 series may also be used in association with GLA and/or DGLA.

Abstract translation: γ-亚麻酸（GLA）和/或二氢-γ-亚麻酸（DGLA）可用于治疗外阴营养不良和/或阴道干燥。 n-6或n-3系列的其他必需脂肪酸也可以与GLA和/或DGLA结合使用。